AGT’s HIV Cure Cell Therapy Clears First Safety Hurdle with DSMB Nod

Published on :

American Gene Technologies’ goal to develop a cure for HIV moved one step closer to reality. After infusing the first patient with its cell therapy candidate AGT103-T, the company announced the Data and Safety Monitoring Board unanimously supported the continuation of the clinical study without modification.

First Participant Infused with Potential HIV Cure Enters Phase 1 Clinical Trials via American Gene Technologies AGT103-T

HIV Cure
Published on :

One year after receiving the green light from the FDA to initiate a Phase I study of an HIV gene therapy, American Gene Technologies (AGT) has infused the first patient. AGT103-T is designed as a cure for the disease that has wreaked havoc across the globe since the 1980s.

LGBT+ investment firm Gaingels joins American Gene Technologies’ mission to cure HIV, and other serious human diseases

LGBT+ investment firm Gaingels joins American Gene Technologies
Published on :

American Gene Technologies (AGT), an emerging gene and cell therapy company, announced today that Gaingels, a leading venture investment syndicate in service of the LGBT+ community and its allies, made an investment in AGT to support the Phase 1 clinical trial of an HIV cure. The Phase 1 human trial is investigating the safety of AGT103-T, a single dose, autologous cell therapy intended to cure the disease. This investment places Gaingels alongside private investors who believe deeply in AGT’s mission, rapid drug development platform, and gene and cell therapy programs for HIV, cancer, and PKU.

ATCC Announces Award of HIV Reagent Program

ATCC is a premier global biological materials and information resource and standards organization and the leading developer and supplier of authenticated cell lines and microorganisms.
Published on :

ATCC, the world’s premier biological materials management and standards organization, today announced that it has been awarded a three-year, $9.86 million task order contract by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to manage and operate its HIV Reagent Program, formerly known as the AIDS Reagent Program. ATCC is tasked to supply the HIV/AIDS research community with no-cost, high-quality materials supporting the development and evaluation of therapeutics, vaccines, and diagnostics.